Canakinumab shown to reduce rates of gout in atherosclerosis by more than half

June 15, 2018, European League Against Rheumatism

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level.

"These are significant results as they add to the evidence base demonstrating a potential preventative role for canakinumab in patients with gout," said Professor Robert Landewé, Chairperson of the Scientific Programme Committee, EULAR. "They will also contribute to our understanding of the interaction between gout, uric acid and cardiovascular disease."

Gout is a very common condition. It is caused by deposits of crystals of a substance called (also known as urate) in the joints, which leads to inflammation. Periods of time when gout symptoms occur are called flares. Flares can be unpredictable and debilitating, developing over a few hours and causing severe pain in the joints.

Canakinumab is a monoclonal antibody that blocks an inflammatory pathway mediated by interleukin-1β. It is licenced for the treatment of several rare auto-inflammatory disorders although it can also be used to treat flares in certain patients with gout who have contraindications to standard therapies.2 There have been some reports to date of efficacy in preventing flares, however canakinumab is currently not approved for this indication.

"Our results demonstrate a striking effect of canakinumab on reducing the risk of in atherosclerosis patients," said Daniel Solomon, Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital. "Moreover, these data illustrate serum urate as a risk marker for both gout and cardiovascular events, though canakinumab has no effect on serum urate levels due to its mechanism of action."

This report is a secondary analysis of the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial which studied the impact of canakinumab in the secondary prevention of cardiovascular (CV) events.3 For this analysis, all participants were divided into three groups based on their serum urate level at baseline; low (<6.9mg/dl), medium (6.9-8.9mg/dl), and high (?9.0 mg/dL). Canakinumab (pooled doses) significantly reduced the rate of flares of gout by more than half compared to placebo, across all baseline serum urate groups. The hazard ratio (95% confidence interval) was 0.40 (0.22-0.73), 0.48 (0.31-0.74), and 0.45 (0.28-0.72) for the low, medium and high baseline serum urate groups respectively. The serum urate levels were not affected by canakinumab over time, although it did reduce high sensitivity C-reactive protein (hsCRP).

By studying the rates of flares of gout and major CV events between the baseline serum urate groups, investigators demonstrated a correlation confirming it as a risk marker for both these conditions. Rates per 100-person years for the low, medium, and high baseline serum urate groups were 0.28, 1.36, and 5.94 respectively for gout-flares, and 4.1, 5.3, 5.6 respectively for major adverse CV events.

The study included 10,061 patients with stable atherosclerosis (prior heart attack) and a hsCRP 2mg/L which indicates an increased risk of CV disease. Patients were randomly assigned to receive placebo or one of three doses of canakinumab (50mg, 150mg, or 300mg) once every three months. The groups were well balanced with respect to their baseline characteristics with a median follow-up time of 3.7 years. Median age was 61 years, 74% were male, median BMI was 29.8kg/m2, median serum urate level at baseline was 6.1 mg/dl.

Serum urate and hsCRP were tested at baseline and every three months for the first year and then annually. A physician diagnosed history of gout was ascertained at baseline and subsequent attacks were assessed during follow-up as part of the systematic adverse event reporting. The rates of attacks and major adverse CV events (heart attack, stroke, re-vascularisation, and CV death) were compared across different baseline urate levels and by randomised treatment assignment.

In the results from the original trial, neutropenia was more common among patients who were assigned to receive canakinumab than among those in the placebo group, and significantly more deaths were attributed to infection or sepsis in the pooled canakinumab groups than in the placebo group (incidence rate 0.31 vs. 0.18 events per 100 person-years; P=0.02). Thrombocytopenia was more common among patients who were assigned to receive canakinumab than among those in the placebo group, but no significant difference in the incidence of haemorrhage was observed.

Explore further: Daily text message may improve adherence and treatment outcomes in patients with gout

More information: Abstract number: OP0014, DOI: 10.1136/annrheumdis-2018-eular.1567

Related Stories

Daily text message may improve adherence and treatment outcomes in patients with gout

June 14, 2018
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate significant improvements in adherence and clinical outcomes in gout patients who received a daily text message ...

Gout in the elderly linked to higher risk of dementia

June 15, 2018
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest that gout is associated with a 17-20% higher risk of dementia in the elderly.

Febuxostat prevents gout flares in recent clinical trial

October 4, 2017
As reported in the journal Arthritis & Rheumatology, the drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout. Febuxostat treatment also reduced synovitis—or inflammation ...

Gout not associated with increased risk of fracture, study finds

May 14, 2018
Gout, a painful inflammatory arthritis, is not associated with an increased risk of fracture, according to a large study led by Keele University, and published in CMAJ (Canadian Medical Association Journal).

Drug combination benefits patients with tophaceous gout

June 9, 2017
The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout. Over 12 months, significantly more patients ...

Canakinumab doesn't prevent prediabetes from progressing to diabetes

March 12, 2018
The anti-inflammatory drug canakinumab had no effect on rates of newly diagnosed diabetes in people who had prediabetes (elevated blood sugar levels at risk of developing into diabetes), according to research presented at ...

Recommended for you

Dietary carbohydrates could lead to osteoarthritis, new study finds

August 9, 2018
Do your knees ache? According to new findings from the Oklahoma Medical Research Foundation, your diet could be a culprit.

Joint study raises questions about treatments for arthritis

August 3, 2018
A study examining how molecules are transported into knee-joint tissue could have major implications for understanding and treating arthritis.

Researchers identify new arthritis severity gene

July 26, 2018
A new gene associated with disease severity in models of rheumatoid arthritis has been identified by researchers at the Icahn School of Medicine at Mount Sinai. The discovery could provide a new pathway for treatment and ...

How the brain plays a role in rheumatoid arthritis inflammation

June 18, 2018
In patients with chronic inflammatory conditions, such as rheumatoid arthritis, there has been limited understanding of how this inflammation affects the brain.

New 3-D imaging analysis technique could lead to improved arthritis treatment

June 18, 2018
An algorithm to monitor the joints of patients with arthritis, which could change the way that the severity of the condition is assessed, has been developed by a team of engineers, physicians and radiologists led by the University ...

Joint resolution: A link between Huntington's disease and rheumatoid arthritis

May 15, 2018
Using new analytic tools, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have decoded the epigenetic landscape for rheumatoid arthritis (RA), a common ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.